Covered recipient · General Payments record
ARVIND MADAN
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$123,374.98
220 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $51,410.00 | 14 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $51,050.00 | 16 |
| Travel and Lodging | $10,525.05 | 40 |
| Food and Beverage | $6,033.93 | 148 |
| Honoraria | $4,356.00 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | $39,347.89 | 28 |
| Amgen Inc. | $22,181.46 | 33 |
| Novartis Pharmaceuticals Corporation | $18,433.50 | 22 |
| AKEBIA THERAPEUTICS INC | $9,471.58 | 9 |
| Kyowa Kirin, Inc. | $9,172.38 | 16 |
| AstraZeneca Pharmaceuticals LP | $8,593.73 | 20 |
| CALLIDITAS THERAPEUTICS US INC. | $6,583.13 | 14 |
| Apellis Pharmaceuticals, Inc. | $2,556.00 | 1 |
| CSL Behring | $2,111.22 | 7 |
| ANI Pharmaceuticals, Inc. | $1,800.00 | 1 |
| Bayer Healthcare Pharmaceuticals Inc. | $1,391.95 | 13 |
| Renalytix AI, Inc. | $292.10 | 6 |
| Vifor Pharma, Inc. | $205.94 | 5 |
| Travere Therapeutics, Inc. | $201.10 | 9 |
| Otsuka America Pharmaceutical, Inc. | $198.16 | 7 |
| Aurinia Pharma U.S., Inc. | $184.06 | 7 |
| GlaxoSmithKline, LLC. | $180.04 | 4 |
| Ardelyx, Inc. | $97.17 | 5 |
| VERTEX PHARMACEUTICALS INCORPORATED | $90.23 | 1 |
| Baxter Healthcare | $62.64 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $47.18 | 2 |
| Novo Nordisk Health Care AG | $44.52 | 1 |
| Alnylam Pharmaceuticals Inc. | $43.29 | 2 |
| CORDIS US CORP. | $41.03 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.18 | 1 |
| Janssen Biotech, Inc. | $21.50 | 1 |
Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ARVIND MADAN
NPI 1235104209 · CMS profile ID 191458
Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
ORLANDO, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1235104209?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ARVIND MADAN, NPI 1235104209, CMS profile ID 191458. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235104209?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ARVIND MADAN, NPI 1235104209, CMS profile ID 191458. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235104209?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ARVIND MADAN, NPI 1235104209, CMS profile ID 191458, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1235104209?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
220 matching records · $123,374.98 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 220.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Kyowa Kirin, Inc. | $11.61 | 10/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025820 | CMS |
| ANI Pharmaceuticals, Inc. | $1,800.00 | 10/04/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091136161 | CMS |
| Novartis Pharmaceuticals Corporation | $20.41 | 10/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087070200 | CMS |
| Ardelyx, Inc. | $17.23 | 10/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146693294 | CMS |
| Travere Therapeutics, Inc. | $6.48 | 09/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149874083 | CMS |
| Amgen Inc. | $3,000.00 | 09/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117316286 | CMS |
| Travere Therapeutics, Inc. | $32.61 | 09/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149874107 | CMS |
| Otsuka America Pharmaceutical, Inc. | $29.07 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118933336 | CMS |
| Novartis Pharmaceuticals Corporation | $73.73 | 09/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087070188 | CMS |
| Amgen Inc. | $121.82 | 09/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117316282 | CMS |
| Novartis Pharmaceuticals Corporation | $132.19 | 09/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087070186 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,400.00 | 09/12/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104432343 | CMS |
| Vifor Pharma, Inc. | $25.15 | 09/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1124056993 | CMS |
| AstraZeneca Pharmaceuticals LP | $109.88 | 09/06/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104589628 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 09/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105728575 | CMS |
| Travere Therapeutics, Inc. | $4.59 | 09/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149874079 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,200.00 | 08/29/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105477713 | CMS |
| AstraZeneca Pharmaceuticals LP | $68.01 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105499914 | CMS |
| Aurinia Pharma U.S., Inc. | $21.48 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150686665 | CMS |
| Aurinia Pharma U.S., Inc. | $0.58 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150686667 | CMS |
| Kyowa Kirin, Inc. | $12.33 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025796 | CMS |
| Kyowa Kirin, Inc. | $2.87 | 08/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025798 | CMS |
| Kyowa Kirin, Inc. | $38.26 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025806 | CMS |
| Kyowa Kirin, Inc. | $7,700.00 | 08/21/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025810 | CMS |
| Kyowa Kirin, Inc. | $24.12 | 08/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025814 | CMS |
| Kyowa Kirin, Inc. | $48.00 | 08/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025816 | CMS |
| Novartis Pharmaceuticals Corporation | $27.98 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087070198 | CMS |
| Otsuka America Pharmaceutical, Inc. | $28.89 | 08/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118933334 | CMS |
| Mallinckrodt Hospital Products Inc. | $11.31 | 08/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145102083 | CMS |
| Mallinckrodt Hospital Products Inc. | $34.00 | 08/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145102087 | CMS |
| Mallinckrodt Hospital Products Inc. | $25.46 | 08/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145102092 | CMS |
| Kyowa Kirin, Inc. | $50.00 | 08/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025800 | CMS |
| Kyowa Kirin, Inc. | $25.00 | 08/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025802 | CMS |
| Kyowa Kirin, Inc. | $25.00 | 08/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025804 | CMS |
| Kyowa Kirin, Inc. | $50.00 | 08/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025818 | CMS |
| Kyowa Kirin, Inc. | $841.78 | 08/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025808 | CMS |
| Kyowa Kirin, Inc. | $226.86 | 08/09/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1127025812 | CMS |
| Renalytix AI, Inc. | $110.83 | 08/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 1116759410 | CMS |
| Renalytix AI, Inc. | $20.73 | 08/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: CHANGED | 06/30/2026 | 1116759408 | CMS |
| Amgen Inc. | $25.81 | 08/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117316264 | CMS |
| Amgen Inc. | $20.10 | 08/05/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117316272 | CMS |
| Amgen Inc. | $2,700.00 | 08/05/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117316274 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $20.06 | 08/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086233348 | CMS |
| GlaxoSmithKline, LLC. | $120.17 | 07/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116556393 | CMS |
| Mallinckrodt Hospital Products Inc. | $7,200.00 | 07/30/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145102079 | CMS |
| Vifor Pharma, Inc. | $65.28 | 07/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1124055038 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $22.06 | 07/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141519115 | CMS |
| Baxter Healthcare | $15.90 | 07/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120586630 | CMS |
| GlaxoSmithKline, LLC. | $20.36 | 07/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116650475 | CMS |
| Janssen Biotech, Inc. | $21.50 | 07/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078468228 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,112,210.00 | 91 |
| PY2024 | Recipient | $169,467.00 | 2 |
| PY2024 | Principal investigator | $2,637,805.42 | 47 |
| PY2023 | Principal investigator | $3,676,573.98 | 9 |
| PY2022 | Principal investigator | $309,956.40 | 5 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
91 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $375.00 | 12/19/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223290012 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $526.40 | 12/19/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223290014 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $22,129.00 | 12/18/2025 | Non-covered Recipient Entity CTR OAKWATER | a phase I and IIa randomized,double blind,placebo controlled study to evaluate the safety and pharmacokinetics of AZD7760 in healthy participants and in patients with end stage kidney disease receiving hemodialysis through a central venous catheter | No dispute reported | 06/30/2026 | 1185543506 |
| Principal investigator 1 | CSL Behring | $1,200.00 | 12/18/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667601 |
| Principal investigator 1 | Calliditas Therapeutics US Inc. | $100.00 | 12/15/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | Nef-403 | No dispute reported | 06/30/2026 | 1235023532 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $150.00 | 12/12/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223289680 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $150.00 | 12/12/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223289684 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $150.00 | 12/10/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223289510 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $394.80 | 12/10/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223289516 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $450.00 | 12/05/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223289276 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $263.20 | 12/05/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223289286 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $75.00 | 12/05/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223289294 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 12/05/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223289372 |
| Principal investigator 1 | Amgen Inc. | $23,500.00 | 11/22/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | No dispute reported | 06/30/2026 | 1246640553 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $100.00 | 11/21/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211591405 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $75.00 | 11/21/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223288659 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $625.00 | 11/12/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223288227 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $75.00 | 11/05/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223288009 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 11/05/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223288011 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 11/05/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223288013 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $100.00 | 11/05/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223288015 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,699.00 | 10/29/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211591393 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,600.00 | 10/29/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211591397 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $14,500.00 | 10/29/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | Double blind study to determine efficacy of ASO Factor B in IgAN | No dispute reported | 06/30/2026 | 1211591401 |
| Principal investigator 1 | Calliditas Therapeutics US Inc. | $1,000.00 | 10/07/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | Nef-403 | No dispute reported | 06/30/2026 | 1235023500 |
| Principal investigator 1 | Amgen Inc. | $72,265.69 | 09/24/2025 | Non-covered Recipient Entity CLINTRIAL RESEARCH OAKWATER, LLC | A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | No dispute reported | 06/30/2026 | 1246640419 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $32,739.84 | 09/24/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy | No dispute reported | 06/30/2026 | 1214125264 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $66,778.34 | 09/17/2025 | Non-covered Recipient Entity CENTRAL FLORIDA KIDNEY SPECIALISTS | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria | No dispute reported | 06/30/2026 | 1185543496 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $55,911.41 | 08/29/2025 | Non-covered Recipient Entity CENTRAL FLORIDA KIDNEY SPECIALISTS | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185543500 |
| Principal investigator 1 | Calliditas Therapeutics US Inc. | $1,100.00 | 08/12/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | Nef-403 | No dispute reported | 06/30/2026 | 1235023468 |
| Principal investigator 1 | CSL Behring | $16.71 | 08/06/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667621 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $400.00 | 08/05/2025 | Non-covered Recipient Entity Elixia Central Florida Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225413615 |
| Principal investigator 1 | Eli Lilly and Company | $55,253.85 | 07/22/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187878663 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $42,218.55 | 07/18/2025 | Non-covered Recipient Entity CTR OAKWATER | a phase 3,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin a nephropathy IgAN | No dispute reported | 06/30/2026 | 1185543502 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $4,049.85 | 07/18/2025 | Non-covered Recipient Entity ELIXIA | a phase 3,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin a nephropathy IgAN | No dispute reported | 06/30/2026 | 1185543508 |
| Principal investigator 1 | CSL Behring | $4,228.00 | 07/16/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667599 |
| Principal investigator 1 | Eli Lilly and Company | $30,614.42 | 07/14/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187880990 |
| Principal investigator 1 | CSL Behring | $600.00 | 07/07/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667595 |
| Principal investigator 1 | CSL Behring | $1,350.00 | 07/07/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667597 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $18,000.00 | 07/07/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223282378 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 07/02/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223282184 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 07/02/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223282186 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 07/02/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition | No dispute reported | 06/30/2026 | 1223282188 |
| Principal investigator 1 | CSL Behring | $2,367.00 | 06/30/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667593 |
| Principal investigator 1 | CSL Behring | $175.00 | 06/23/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667589 |
| Principal investigator 1 | CSL Behring | $750.00 | 06/23/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667591 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $1,374.00 | 06/18/2025 | Non-covered Recipient Entity Elixia Central Florida, LLC | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930846 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,000.00 | 06/13/2025 | Non-covered Recipient Entity Elixia Central Florida Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225412406 |
| Principal investigator 1 | CSL Behring | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667587 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,439.00 | 06/05/2025 | Non-covered Recipient Entity Elixia Central Florida Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225412180 |
| Principal investigator 1 | CSL Behring | $4,734.00 | 05/14/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667585 |
| Principal investigator 1 | Calliditas Therapeutics US Inc. | $9,600.00 | 05/12/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | Nef-403 | No dispute reported | 06/30/2026 | 1235023432 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $3,995.00 | 05/07/2025 | Non-covered Recipient Entity Elixia Central Florida, LLC | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243930765 |
| Principal investigator 1 | CSL Behring | $600.00 | 05/05/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667581 |
| Principal investigator 1 | CSL Behring | $2,000.00 | 05/05/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667583 |
| Principal investigator 1 | CSL Behring | $1,861.00 | 04/25/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667579 |
| Principal investigator 1 | CSL Behring | $10,660.00 | 04/16/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667577 |
| Principal investigator 1 | CSL Behring | $16.71 | 04/11/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667619 |
| Principal investigator 1 | CSL Behring | $16.71 | 04/10/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667615 |
| Principal investigator 1 | CSL Behring | $97.31 | 04/10/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667617 |
| Principal investigator 1 | Calliditas Therapeutics US Inc. | $10,000.00 | 04/10/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | Nef-403 | No dispute reported | 06/30/2026 | 1235023422 |
| Principal investigator 1 | CSL Behring | $605.38 | 04/08/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667613 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $86.00 | 03/27/2025 | Non-covered Recipient Entity Elixia Central Florida Llc | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225404640 |
| Principal investigator 1 | CSL Behring | $5,452.00 | 03/19/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667575 |
| Principal investigator 1 | Aurinia Pharma U.S., Inc. | $20,283.76 | 03/12/2025 | Non-covered Recipient Entity Elixia Central Florida, LLC | LUPKYNIS Registry Study | No dispute reported | 06/30/2026 | 1243931056 |
| Principal investigator 1 | CSL Behring | $725.86 | 02/21/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667611 |
| Principal investigator 1 | CSL Behring | $500.00 | 02/19/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667571 |
| Principal investigator 1 | CSL Behring | $7,120.00 | 02/19/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667573 |
| Principal investigator 1 | CSL Behring | $15.15 | 02/19/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667609 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,240.00 | 02/06/2025 | Non-covered Recipient Entity Elixia Central Florida Llc | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225405194 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $220.00 | 01/28/2025 | Non-covered Recipient Entity Elixia Central Florida Llc | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225403115 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $678.00 | 01/27/2025 | Non-covered Recipient Entity Elixia Central Florida Llc | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225406516 |
| Principal investigator 1 | Eli Lilly and Company | $2,560.94 | 01/27/2025 | Non-covered Recipient Entity ELIXIA COVID-19 LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187881698 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $27,366.24 | 01/27/2025 | Non-covered Recipient Entity ELIXIA CLINICAL RESEARCH COLLABORAT | A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy | No dispute reported | 06/30/2026 | 1190309338 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $81,107.77 | 01/27/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease | No dispute reported | 06/30/2026 | 1214125572 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $60,694.20 | 01/24/2025 | Non-covered Recipient Entity ELIXIA | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria | No dispute reported | 06/30/2026 | 1185543494 |
| Principal investigator 1 | CSL Behring | $2,740.00 | 01/24/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667553 |
| Principal investigator 1 | Eli Lilly and Company | $86,826.00 | 01/21/2025 | Non-covered Recipient Entity ELIXIA CENTRAL FLORIDA LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187880569 |
| Principal investigator 1 | Eli Lilly and Company | $77,141.00 | 01/21/2025 | Non-covered Recipient Entity ELIXIA CENTRAL FLORIDA LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187880571 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $599.21 | 01/15/2025 | Non-covered Recipient Entity ELIXIA CLINICAL RESEARCH COLLABORAT | An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids i | No dispute reported | 06/30/2026 | 1190309340 |
| Principal investigator 1 | AstraZeneca UK Limited | $204,548.45 | 01/13/2025 | Non-covered Recipient Entity ELIXIA | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185543498 |
| Principal investigator 1 | CSL Behring | $11,537.00 | 01/10/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667549 |
| Principal investigator 1 | CSL Behring | $14,316.00 | 01/10/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667551 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $572,434.80 | 01/10/2025 | Non-covered Recipient Entity ELIXIA CENTRAL FL | An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3) | No dispute reported | 06/30/2026 | 1214124708 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,305.00 | 01/09/2025 | Non-covered Recipient Entity Elixia Central Florida Llc | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225406514 |
| Principal investigator 1 | CSL Behring | $797.36 | 01/08/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667605 |
| Principal investigator 1 | CSL Behring | $97.31 | 01/08/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667607 |
| Principal investigator 1 | CSL Behring | $30.26 | 01/07/2025 | Non-covered Recipient Entity Elixia Central Florida LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1252667603 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,790.80 | 01/03/2025 | Non-covered Recipient Entity ELIXIA | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185543504 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $226,079.77 | 01/02/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER) | No dispute reported | 06/30/2026 | 1214123532 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $173,061.95 | 01/01/2025 | Non-covered Recipient Entity CTR OAKWATER LLC | A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease | No dispute reported | 06/30/2026 | 1214125574 |